Merck jumps as lab demand lifts 2026 outlook

Merck KGaA

13/05/2026 07:35

** Germany's Merck MRCG.DE is up 4.4% in early Frankfurt trade after it raised its full-year guidance on stronger demand for its lab supplies and delayed competition for its Mavenclad multiple sclerosis drug

** The science and healthcare firm also reported higher-than-expected Q1 EBITDA of 1.53 billion euros, beating average analyst expectations of 1.46 billion euros

** "Given the strong set of results and FY’26 Guidance upgrade... we expect the shares to outperform by 2-3% today," JPMorgan says

** The stock is at the top of German blue-chip index DAX .GDAXI in early Frankfurt trade

 (Reporting by Emanuele Berro)

 ((emanuele.berro@thomsonreuters.com))